This report analyzes the worldwide markets for Chronic Obstructive Pulmonary Disease in US$ Million. The report provides separate comprehensive analytics for US and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. Continue Reading

Sudden Cardiac Arrest syndrome (SCA) is poorly understood, but it’s a real danger for the otherwise young and healthy. For no apparent reason, the heart suddenly stops beating, and without treatment death may follow within minutes. It’s why some athletes drop dead on the track and why a young man, without any warning, suddenly dies while sitting at his desk. Continue Reading

A $6 million grant from the National Heart, Lung and Blood Institute (NHLBI) has funded the creation of ORBIT: Obesity Related Behavioral Intervention Trials to focus on reducing obesity and obesity-related deaths in New York City’s African-American and Latino communities. Continue Reading

M. D. Anderson Cancer Center are encouraging men and women to learn more about colon polyps and how they affect a person’s risks for cancer. Continue Reading

Indianapolis resident Harry Traugott was an active retiree, participating in community events, driving and even teaching English as a second language at two community centers.br /br /He’d been diagnosed with age-related macular degeneration (AMD), but the disease had not caused significant vision loss. It wasn’t until he had trouble seeing while driving, watching television Continue Reading

Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review. Continue Reading

The Cancer Prevention and Research Institute of Texas today awarded over $6.8 million to fund twelve new cancer prevention programs through local clinics, health districts, community-based organizations, and academic institutions across the state of Texas. Continue Reading

Oculus Innovative Sciences, Inc., a commercial medical technology company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, today announced that it has received new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new dermatology indications for Microcyn® Skin and Wound HydroGel. Continue Reading

The annual Harris Poll that has measured key health risks – smoking, seat belt use, weight and obesity – for the last 28 years, provides both good and bad news. Continue Reading

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE® (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will continue to make available branded Timoptic-XE. Continue Reading